Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Family with sequence similarity 91 member A2, pseudogene (FAM91A2P) is classified as a *pseudogene*, meaning it is a genomic DNA sequence similar to a known gene but typically nonfunctional, due to disabling mutations or absence of regulatory sequences[3][5]. Pseudogenes in general were traditionally considered "junk" DNA; however, some have been shown to have regulatory roles in gene expression through RNA-based mechanisms such as acting as decoys for microRNAs or producing small interfering RNAs[1]. There is currently no evidence that FAM91A2P is transcribed or functional, and it is not recognized as a target for any therapeutic drugs. No mutations or syndromes have been explicitly linked to this pseudogene. If pursuing structured database annotation, this entry should be marked as a pseudogene and not as a targetable molecular entity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Family with sequence similarity 91 member A2, pseudogene (FAM91A2P).